Growth Metrics

Castle Biosciences (CSTL) Equity Income (2024 - 2026)

Castle Biosciences' Equity Income history spans 2 years, with the latest figure at -$1.9 million for Q4 2025.

  • On a quarterly basis, Equity Income fell 434.23% to -$1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 171.17% increase, with the full-year FY2025 number at $1.5 million, up 164.14% from a year prior.
  • Equity Income hit -$1.9 million in Q4 2025 for Castle Biosciences, down from $3.6 million in the prior quarter.
  • Over the last five years, Equity Income for CSTL hit a ceiling of $3.6 million in Q3 2025 and a floor of -$1.9 million in Q4 2025.